Risankizumab to treat moderately to severely active Crohn’s disease in adults: an evaluation of trials and data

IF 3.8 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Expert Review of Gastroenterology & Hepatology Pub Date : 2023-12-14 DOI:10.1080/17474124.2023.2295496

Amanda M. Johnson, Edward V. Loftus Jr.

引用次数: 0

Abstract

Risankizumab is a humanized monoclonal antibody that selectively inhibits interleukin (IL)-23. It is approved for the treatment of moderate-to-severe plaque psoriasis, psoriatic arthritis, and more...

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

利桑珠单抗治疗成人中度至重度活动性克罗恩病：试验和数据评估

利桑珠单抗是一种选择性抑制白细胞介素（IL）-23的人源化单克隆抗体。它已被批准用于治疗中重度斑块状银屑病、银屑病关节炎等。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Expert Review of Gastroenterology & Hepatology GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

6.80

自引率

2.60%

发文量

审稿时长

6-12 weeks

期刊介绍： The enormous health and economic burden of gastrointestinal disease worldwide warrants a sharp focus on the etiology, epidemiology, prevention, diagnosis, treatment and development of new therapies. By the end of the last century we had seen enormous advances, both in technologies to visualize disease and in curative therapies in areas such as gastric ulcer, with the advent first of the H2-antagonists and then the proton pump inhibitors - clear examples of how advances in medicine can massively benefit the patient. Nevertheless, specialists face ongoing challenges from a wide array of diseases of diverse etiology.

期刊最新文献

Extraintestinal complications of celiac disease: treatment considerations. Advancements in the management of pediatric inflammatory bowel disease. Exploring immunological perturbations between hepatocellular carcinoma risk, inflammation and obesity. Colonic diverticular disease revisited. When to refer patients for liver elastography.